Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Irras AB (IRRAS) NPV

Sell:6.00 SEK Buy:6.12 SEK Change: 0.1 SEK (1.61%)
Market closed |  Prices as at close on 19 April 2021 | Switch to live prices |
Sell:6.00 SEK
Buy:6.12 SEK
Change: 0.1 SEK (1.61%)
Market closed |  Prices as at close on 19 April 2021 | Switch to live prices |
Sell:6.00 SEK
Buy:6.12 SEK
Change: 0.1 SEK (1.61%)
Market closed |  Prices as at close on 19 April 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Irras AB is a Sweden-based medical technology company. It offers devices for fluid control and management for a broad range of brain pathologies, central nervous system (CNS) therapeutic applications and procedures. The offer comprises instruments and catheters for the clinical, monitoring and surgical applications for brain pathology indications called IRRAflow. The IRRAflow CNS System combines an External Drainage System, an intracranial pressure monitoring (ICP) Monitor and an Occlusion Solution Mechanism into a single, integrated device. The primary market for IRRAflow is the United States. The Company’s shareholders comprise Vandel Medical Equipment (CY) Limited, Serendipity Ixora AB (publ) and F.EX Endotherapy Limited, among others.

Contact details

Address:
Vasagatan 16
STOCKHOLM
111 20
Sweden
Telephone:
+46 (8) 102115170
Website:
https://irras.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IRRAS
ISIN:
SE0008321202
Market cap:
412.93 million SEK
Shares in issue:
66.28 million
Sector:
Health Care Equipment
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Marios Fotiadis
    Independent Chairman of the Board
  • Kleanthis Xanthopoulos
    President, Chief Executive Officer, Director
  • Sabina Berlin
    Chief Financial Officer
  • Adam Sampson
    Vice President - Product Excellence
  • Kellie Fontes
    Senior Director, Human Capital
  • Will Martin
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.